Over the past year or so, the system for issuing VISAs and work permits in the UK has changed dramatically. A knowledge of the practical implications of the new system will be vital for anyone hoping to bring their skills to the pharmaceutical industry in this country
The phrase Halcyon days is a literary commonplace in the English language English language and culture, signifying ideals of prosperity, bonhomie, joy, liberation, or tranquility. I can testify to experiencing all these sentiments having worked in Clinical R&D for nearing 30 years. I'm not so certain we'll ever return to the same again though.
Ann Maloney BSc FICR
I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
The craving for cheap drugs has never been greater. For those patients and policymakers in developing countries, the existence of parallel imports is less a concern than a blessing. Yet for pharmaceutical companies themselves, there is the concern that an increasing trade in parallel imports would severely damage research-intensive activities and ultimately slow down the development of the very same drugs that are being traded in ‘grey’ markets today.
Ever since the H1N1 virus first came onto the world map in April, ‘Where’s the vaccine?’ has been the cardinal question on everybody’s lips. As world governments scrambled to control the outbreak, supranational bodies such as the World Health Organization (WHO) threw themselves at the task of producing weekly updates for a virus which we originally knew very little about.
It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen
Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners
In the eyes of many graduates, the economic recession has brought a new-found negativity to the job market. Thankfully, the climate is probably less dire than the situation sometimes imagined.
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen
Max Golby, Freelance Journalist, takes a look at the history of the e-Detailing market, considers what the e-Detail of the future might look like and asks what marketing departments can learn from an academic analysis of the instrument.
As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
Generational stereotypes are never easy to swallow, but when it comes to doctors and an investment in social media, the new generations of medical professionals are increasingly going online for both professional collaboration and patient support.
With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.
Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.
Unless it paints the right picture you’re letting the side down!
In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who ‘piggy back’ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD
Senior Department of Health executives, speaking at a recent NHS Alliance Conference, suggested that the NHS has two years left before it starts to the credit crunch’s bite – maybe less if there is an election in a years’ time. But this should not be cause complacency in the health sector. The message is, invest wisely now so that you are well prepared for the fallow times ahead.
The growing incidence of diseases and conditions related to aging is creating pockets of opportunity for pain management. These opportunities include the expanding use of prescription NSAIDs as second-line therapies for chronic pain and an increase in off-label prescribing. As populations and indications evolve, so too is the pain management sector.
Applied Data Research
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her